PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Operating income 2016–2025
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) annual operating income history from SEC filings — each fiscal year as reported.
-$5.3MFY2025 · since FY2016: -$24.5M → -$5.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$5.3M | -16.8% |
| FY2024 | -$4.5M | -56.2% |
| FY2023 | -$2.9M | +15.4% |
| FY2022 | -$3.4M | +26.6% |
| FY2021 | -$4.7M | +5.9% |
| FY2020 | -$5.0M | +21.2% |
| FY2019 | -$6.3M | +21.8% |
| FY2018 | -$8.1M | +39.5% |
| FY2017 | -$13.3M | +45.7% |
| FY2016 | -$24.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PVCT financial trends
PVCT RevenuePVCT Net incomePVCT Net marginPVCT Gross profitPVCT Gross marginPVCT Operating marginPVCT Operating cash flowPVCT Free cash flowPVCT Capital expendituresPVCT Return on equityPVCT Stock buybacksPVCT Dividends paidPVCT Total assetsPVCT Total liabilitiesPVCT Shareholders’ equityPVCT overview →